FogPharma

We’re excited to welcome Karthik Sriram as our new Vice President, Financial Planning & Analysis. ? With over 16 years of experience in pharma and biotech, Karthik brings extensive expertise in financial management, strategic planning, and business development. Karthik’s addition to our leadership team will help drive our continued progress to fundamentally change treatment possibilities for cancer and other diseases with critical need. ? We’re glad to have you on the team, Karthik! #Biotech #Finance

We’re proud to recognize a number of talented team members who have recently received promotions.?? Having a growth mindset is a key part of our identity at Fog. It drives us to be constantly curious, to creatively knock down barriers standing in our way, and to pursue things others might dismiss as impossible.?? Mitchell Larios, Sophie Minniti, Clare Fraser, Erica Visness, Kerry Marasa Cadigan, Warren (Ed) Dorsch, Diwakar Pattabiraman, Olena Tokareva, PhD, and Amanda Garofalo, congratulations on your new role! We’re looking forward to continuing to grow together.? #TeamPromotions?

Our CEO Mathai Mammen, M.D., Ph.D. will be speaking at the upcoming #BioCenturyGrandRounds as part of an illustrious panel of biopharma, regulatory and clinical experts entitled “Data for purpose: go big, go deep, or go long?” The panel will discuss how researchers are prioritizing data collection and application in the setting of real-world logistical constraints, and what the future of improved data collection looks like.??? ? Data science is core to our #drugdiscovery and development work at Fog. We’re applying physics-based computational methods and artificial intelligence to aid in the invention of Helicons, a powerful peptide modality capable of “drugging” what has thus far has been completely intractable.? The larger biopharmaceutical ecosystem is starting to pay close attention to the multiple important problems encountered en route to a medicine that can be addressed by emerging technologies.??? Learn more about Grand Rounds and explore the full agenda here: https://lnkd.in/gakuvuEn?? #DataScience #Biotech?

We’d like to introduce the newest member of #TeamFogPharma: Amrith Bennet, our new Associate Vice President, Toxicology. Amrith’s 20+ years of experience in drug discovery and development will deepen the talent of our already-exceptional R&D group. In his role, Amrith will oversee the design and execution of nonclinical safety programs, supporting the development of safe and effective new medicines from discovery through to market authorization.? This new position for Fog will enable us to continue to grow our pipeline and leverage our Helicon technology, in oncology and beyond, to make extraordinary medicines. Welcome to the team, Amrith!? #Biotech #DrugDiscovery?

FogPharma CEO Mathai Mammen, M.D., Ph.D. spoke recently with MIT Sloan CDO about the powerful convergence of the parallel revolutions in the medical sciences and data science (AI), its significance for those aspiring to work in the biopharma industry, and its role in driving the next wave of therapeutic breakthroughs. ? ? Our discovery engine has been custom-built to create a powerful drug modality that allows us to pursue medicines not currently possible anywhere else. We have assembled a top-tier team that relentlessly invents what we need and aims to create unique and effective medicines.??? ?? Read the full article here: https://bit.ly/46ZI3IT ??? ?? #Biotech #MachineLearning #AI?

We’re excited to be partnering with ARTBIO to together create a new category of #radiopharmaceuticals. Recently ARTBIO CEO Emanuele Ostuni spoke with Mayo Clinic medical oncologist Oliver Sartor about the immense therapeutic promise of radiopharmaceuticals and of the Lead-212 manufacturing platform ARTBIO has built. Speaking about our companies’ collaboration, Emanuele highlighted how Helicons’ unique properties enable our co-created medicines to reach a vast range of previously unreachable targets: "Hitting those targets requires conformational specificity that can be had with very specific platforms, such as the one that FogPharma has, with whom we've partnered, to find ligands to targets that aren't classically druggable, as one would say.” Learn more about ARTBIO’s approach and see the full video on UroToday + GU OncToday: https://bit.ly/4ccIz7u #DrugDiscovery #Biotech

As the world cheered on athletes at #Paris2024, we channeled that same spirit of friendly competition at our 4th annual Summer Olympics last week! Featuring events such as pinning sidechains onto Helicons, a pipette tip shooting contest, and a radiopharmaceutical-inspired relay, our version of the summer games put our creativity and problem-solving to the test and produced lots of opportunities for camaraderie and laughter.?? ? We look forward to the Summer Olympics each year as a time to come together and strengthen the bonds that unite us. And in that respect, #TeamFogPharma definitely took home the gold last week! ??? ? Check out some of the highlights below.?? #TeamBuilding #CompanyOffsite?

The Biotech Week Boston Awards celebrate organizations driving innovation in the life sciences, and we have been named a 2024 finalist! We’re proud to be recognized in the Boston Highlight category among other local companies who have had a standout year.? ? And the past year certainly has been momentous for our team as we work toward extraordinary impact for patients: we brought the first-ever Helicon drug candidate to the clinic, expanded our senior management team with several leading biotech executives who will play a critical role in realizing our long-term vision, raised a $145M Series E round and forged a partnership that expands our portfolio into radiopharmaceuticals.? ? See you on September 23rd, when winners will be announced at Biotech Week Boston! https://bit.ly/3Wt722s ?? ? #biotech #oncology #radiopharmaceuticals #biotechweekboston? ?

We’re proud to welcome Teresa Jurgensen, J.D., as the newest addition to our senior management team as General Counsel. Teresa is a seasoned business partner and lawyer who has spent the last two decades working in the biotech and pharma industries. We’re looking forward to Teresa’s partnership in guiding our continued growth as a company and contributing her expertise to all of our current and future strategic initiatives. Welcome to the team, Teresa! #TeamFogPharma #biotechnology

Join us in welcoming the newest addition to the FogPharma leadership team: Alex Hird, Fog’s Vice President, Medicinal Chemistry Design. Alex brings to Fog nearly two decades of experience building and leading high-performing research teams in oncology drug discovery. His expertise targeting difficult-to-drug proteins will be an asset in our work to deploy Helicons against previously intractable targets, and his experience with leading-edge computational design tools will enhance our work to blend data science with biomedical science to discover exceptional new medicines. We’re thrilled to have you on #TeamFogPharma, Alex! #biotechnology #oncology #chemistry